Rallybio
Rallybio works on 3 rare diseases tracked on Trial Friend, including Immune Thrombocytopenia, Myasthenia Gravis, Thyroid Eye Disease.
Rallybio agreed in March 2026 to merge with Candid Therapeutics, but Candid ended the agreement in May 2026 to pursue a deal with UCB, and Rallybio received a termination fee and remains independent. Rallybio previously focused on antibodies and engineered proteins for rare diseases across hematology and other therapeutic areas.
Focus areas at Rallybio
As a rare disease specialist, Rallybio has active clinical trial programs and drug development efforts across 3 rare diseases, including Immune Thrombocytopenia, Myasthenia Gravis, Thyroid Eye Disease. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Rallybio, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Rallybio is headquartered in New Haven, United States, founded in 2018. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Active Clinical Trials
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Rallybio. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Immune Thrombocytopenia. Turn any of these off from the link in every email.
FDA-Approved Drugs
Rare Disease Focus Areas (3)
Diseases targeted by Rallybio's clinical trial and drug development programs
Immune thrombocytopenia (ITP) is a rare autoimmune disorder in which the immune system destroys platelets, the blood cells that stop bleeding, and slows their production. It causes easy bruising, pinp...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies attack acetylcholine receptors at the neuromuscular junction, preventing proper m...
Thyroid eye disease (TED) is a rare autoimmune condition in which the immune system attacks the muscles and fat behind the eyes, causing bulging eyes, double vision, pain, and in severe cases vision l...
Patient Resources
Organizations and resources related to Rallybio's rare disease focus areas
Frequently Asked Questions About Rallybio
Common questions about Rallybio's rare disease programs, clinical trials, and treatments.